A synergistic bactericidal composition containing thiabendazole copper and copper bromide and its preparation method thereof

By preparing a confined dispersion of copper bromide and micronizing thiabendazole copper, combined with proximity composite technology, the problems of dispersion stability and uneven release in the compounding of thiabendazole copper and copper bromide were solved, achieving stable release of copper ions and synergistic bactericidal effect, thus improving the safety and efficacy of pesticides.

CN123100660APending Publication Date: 2026-11-17WUJIANG WEISHIDA COPPER S&T CO LTD
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202611245523.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-08-17
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing thiabendazole copper formulations or compound compositions, when combined with copper bromide, lack synergistic regulation of the dispersion state of thiabendazole copper particles and the release behavior of copper ions from copper bromide, resulting in insufficient dispersion stability, rapid release of copper ions, fluctuating synergistic effects, and the risk of irritation to crop leaves.

Method used

A copper bromide confined dispersion was prepared by dispersing copper bromide with a porous carrier, a protective colloid, and a weak complexing stabilizer in an aqueous phase. Thiamethoxam was then micronized and compounded with the copper bromide confined dispersion in a near-field manner. By controlling the mass ratio of thiamethoxam to copper bromide and the pH, shear, and feeding sequence during the compounding process, a stable dual-copper-source composite dispersion system was formed.

Benefits of technology

It improves the suspension stability, storage stability and application safety of the composition, reduces the risk of copper ion burst release, enhances the control effect on bacterial diseases of crops, and reduces the fluctuation of synergistic effect and the risk of phytotoxicity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123100660A_ABST
    Figure CN123100660A_ABST
Patent Text Reader

Abstract

This invention relates to the field of agricultural fungicide formulation technology, specifically disclosing a synergistic fungicide composition containing thiabendazole copper and copper bromide, and its preparation method. The method involves first dispersing copper bromide with a porous carrier, a protective colloid, and a weak complexing stabilizer in an aqueous phase to obtain a copper bromide confined dispersion; then pre-dispersing thiabendazole copper with a dispersant, wetting agent, and water, followed by wet milling to control the D90 to 2–5 μm, to obtain a thiabendazole copper microparticle dispersion; subsequently, adding the copper bromide confined dispersion in batches or continuously to the thiabendazole copper microparticle dispersion for adjacent compounding, and stabilizing through post-treatment to obtain the composition. This method helps reduce the early burst release of copper ions, improves suspension stability, storage stability, and application safety.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of agricultural fungicide formulation technology, and in particular to a synergistic fungicide composition containing thiabendazole copper and copper bromide and its preparation method. Background Technology

[0002] Thiamethoxam belongs to the organic copper fungicidal active ingredient class and can be used for the control of bacterial diseases and some fungal diseases in crops. Existing technologies already exist for the formulation processing and compound application of thiamethoxam; for example, Chinese invention patent CN104255716B discloses a water-dispersible granule of thiamethoxam and its preparation method. This method combines thiamethoxam with wetting agents, dispersants, disintegrants, binders, defoamers, plant growth regulators, synergists, and fillers, and obtains the water-dispersible granule of thiamethoxam through steps such as mixing, pulverizing or sand milling, granulation, drying, and sieving, thereby improving the disintegration of thiamethoxam formulations. Properties, suspension rate, and thermal storage stability; for example, Chinese invention patent CN110810437B discloses the use of a fungicide composition containing thiamethoxam zinc and thiamethoxam copper, which combines thiamethoxam zinc and thiamethoxam copper to reduce or prevent rice from being infected by toxins formed by rice bacterial leaf streak, and describes the composition being applied in a proportion that has a synergistic effect; it can be seen that optimizing the formulation or compounding synergistic effect of thiamethoxam copper has become a technical direction in the development of copper-containing agricultural fungicides.

[0003] However, existing thiabendazole copper formulations or compound compositions mostly focus on improving the formulation processing, dispersion performance, and storage stability of thiabendazole copper itself, or on the synergistic control effect between thiabendazole copper and other bactericidal active ingredients. When thiabendazole copper is compounded with inorganic copper salts that have a strong tendency to release into the aqueous phase, there is a lack of targeted control over the dispersion state, release rhythm, and compound stability of different copper sources in the formulation system. For compound systems such as thiabendazole copper and copper bromide, thiabendazole copper is usually dispersed in the formulation system in particulate form, and its formulation performance is related to particle size, dispersion uniformity, and suspension stability. Copper bromide... As a copper salt component, if directly added to the thiabendazole copper dispersion system, it may lead to a relatively high local copper ion concentration during the preparation process or at the initial stage of application. This is not conducive to the dispersion stability of the compound system and may increase the risk of rapid early release of copper ions, flocculation and sedimentation of the system, fluctuations in synergistic effects, and irritation to crop leaves. Therefore, how to control the dispersion state and release behavior of copper bromide through the preparation process, and improve its composite stability with the thiabendazole copper particulate dispersion system, is a technical problem that needs to be further solved in the preparation of fungicidal compositions containing thiabendazole copper and copper bromide. Summary of the Invention

[0004] The technical problem to be solved by this invention is that existing thiabendazole copper preparations or compound compositions mostly focus on formulation processing, dispersion stability, or synergistic control effects of active ingredients, lacking synergistic regulation of the dispersion state of thiabendazole copper particles and the release behavior of copper ions from copper bromide. This leads to potential problems such as insufficient dispersion stability, rapid early release of copper ions, fluctuations in synergistic effects, and risks of leaf irritation in directly compounded systems. To solve the above technical problems, this invention provides a synergistic fungicidal composition containing thiabendazole copper and copper bromide and its preparation method.

[0005] To achieve the above objectives, the present invention adopts the following technical solution: a method for preparing a synergistic bactericidal composition containing thiabendazole copper and copper bromide, characterized by comprising the following steps: S1: Copper bromide is dispersed in an aqueous phase with a porous carrier, a protective colloid, and a weak complexing stabilizer to obtain a copper bromide confined dispersion. S2: Pre-disperse thiabendazole copper with dispersant, wetting agent and water, and perform wet milling to control the D90 of thiabendazole copper particles to 2-5 μm to obtain thiabendazole copper microparticle dispersion. S3: Add the copper bromide confined dispersion obtained in step S1 in batches or continuously to the thiabendazole copper microparticle dispersion obtained in step S2, and perform adjacent compounding under shear conditions to obtain a dual copper source composite dispersion system. S4: Add formulation auxiliary components to the dual copper source composite dispersion system obtained in step S3 for post-treatment stabilization to obtain the synergistic bactericidal composition containing thiabendazole copper and copper bromide. The mass ratio of thiabendazole copper to copper bromide is 20:1 to 1:3.

[0006] Preferably, the mass ratio of thiabendazole copper to copper bromide is 10:1 to 1:1.

[0007] Preferably, in step S1, the mass ratio of copper bromide to porous carrier is 1:0.5 to 1:5; after adding copper bromide to water and stirring to dissolve it, porous carrier, protective colloid and weak complexing stabilizer are added, and the mixture is stirred at 25 to 45°C for 30 to 90 minutes to obtain the copper bromide confined dispersion.

[0008] Preferably, the porous carrier is selected from one or more of attapulgite, diatomaceous earth, silica, montmorillonite, bentonite, and magnesium aluminum silicate; the protective colloid is selected from one or more of polyvinylpyrrolidone, polyvinyl alcohol, gum arabic, sodium alginate, and sodium carboxymethyl cellulose; and the weak complexing stabilizer is selected from one or more of sodium citrate, sodium gluconate, sodium tartrate, and sodium acetate.

[0009] Preferably, in step S2, thiabendazole copper, dispersant, wetting agent, defoamer and water are added to a dispersion vessel and sheared at 1000-3000 r / min for 10-40 minutes to obtain thiabendazole copper pre-dispersion; then the thiabendazole copper pre-dispersion is wet-milled to obtain the thiabendazole copper microparticle dispersion.

[0010] Preferably, in step S3, the copper bromide confined dispersion is added to the thiabendazole copper microparticle dispersion over a period of 20 to 60 minutes. During the addition process, the system temperature is controlled at 20 to 35°C, the pH at 5.8 to 6.8, and the shearing speed at 800 to 2000 r / min. After the addition is completed, homogenization is continued for another 20 to 50 minutes.

[0011] Preferably, the dispersant is selected from one or more of lignin sulfonate, naphthalene sulfonate formaldehyde condensate, polycarboxylate dispersant, and alkyl aryl polyoxyethylene ether; the wetting agent is selected from one or more of sodium dodecyl sulfate, sodium dodecylbenzene sulfonate, fatty alcohol polyoxyethylene ether, and alkyl naphthalene sulfonate.

[0012] Preferably, in step S4, the formulation auxiliary components include a thickener, an antifreeze agent, an antifoaming agent, and a pH buffer; the thickener is selected from one or more of xanthan gum, magnesium aluminum silicate, sodium carboxymethyl cellulose, and polyvinyl alcohol; the antifreeze agent is selected from one or more of ethylene glycol, propylene glycol, and glycerol; and the pH buffer is selected from one or more of acetate buffer, citrate buffer, and phosphate buffer.

[0013] A synergistic bactericidal composition containing thiabendazole copper and copper bromide, wherein the synergistic bactericidal composition containing thiabendazole copper and copper bromide is prepared by a method for preparing a synergistic bactericidal composition containing thiabendazole copper and copper bromide.

[0014] Preferably, the synergistic bactericidal composition comprises, by weight: Thiamethoxam 5-40 parts, copper bromide 0.5-15 parts, porous carrier 0.5-12 parts, protective colloid 0.1-5 parts, weak complexing stabilizer 0.05-2 parts, dispersant 1-10 parts, wetting agent 0.5-5 parts, thickener 0.05-3 parts, antifreeze 0-8 parts, defoamer 0.05-1 part, pH buffer 0.05-2 parts, water to make up to 100 parts; The copper bromide, calculated as an effective amount of CuBr2, has a mass ratio of thiabendazole copper to copper bromide of 20:1 to 1:3; the synergistic bactericidal composition is in the form of a suspension.

[0015] The technical effects and advantages of this invention are as follows: In this invention, copper bromide is pre-treated with a porous carrier, a protective colloid, and a weak complexing stabilizer for confined stabilization. Then, thiabendazole copper is micronized and compounded stepwise with the confined copper bromide dispersion. This method prevents copper bromide from being released in a completely free state in the formulation system and maintains a good composite dispersion state between the thiabendazole copper particles and the copper bromide dispersion. Compared with direct mixing compounding methods, this preparation method helps to reduce the sudden release of copper ions from copper bromide during preparation and the initial stage of application, and reduces the adverse effects of excessively high local copper ion concentrations on the thiabendazole copper dispersion system and crop leaves, thereby improving the suspension stability, storage stability, and application safety of the composition.

[0016] Meanwhile, by controlling the mass ratio of thiabendazole copper to copper bromide, the particle size of thiabendazole copper, and the pH, shearing, and feeding sequence during the compounding process, this invention enables the two copper sources to form a better synergistic relationship in terms of bactericidal effect and release behavior. The resulting composition improves the control effect on bacterial diseases of crops while maintaining the continuous release capacity of copper ions, reduces the fluctuation of synergistic effect and the risk of phytotoxicity, and can better balance bactericidal synergistic effect, release stability, formulation stability and crop safety. Attached Figure Description

[0017] The disclosure of this invention is illustrated with reference to the accompanying drawings. It should be understood that the drawings are for illustrative purposes only and are not intended to limit the scope of protection of this invention.

[0018] Figure 1 This is a flowchart illustrating the preparation method of the synergistic bactericidal composition containing thiabendazole copper and copper bromide of the present invention. Figure 2 This is a comparison chart of copper ion release curves in embodiments and comparative examples of the present invention; Figure 3 The figures show a comparison of the storage stability of the compositions in the embodiments and comparative examples of the present invention. In the figure, (a) is a comparison of the suspension rate before and after heat storage, and (b) is a comparison of the volume fraction of the settling layer after heat storage. Figure 4 This is a comparison diagram of the potted plant efficacy and phytotoxicity of the embodiments and comparative examples of the present invention; Figure 5 A graph showing the relationship between the properties of the compositions under different mass ratios of thiabendazole copper to copper bromide; Figure 6 A comparison of the zeta potentials of different composition samples; Figure 7 Images showing the appearance of phytotoxicity on cucumber leaves after different treatments. Detailed Implementation

[0019] It is readily understood that, based on the technical solution of this invention, those skilled in the art can propose various interchangeable structural methods and implementations without altering the essential spirit of the invention. Therefore, the following detailed embodiments and accompanying drawings are merely illustrative examples of the technical solution of this invention and should not be considered as the entirety of the invention or as limitations or restrictions on the technical solution of this invention.

[0020] This embodiment relates to a synergistic bactericidal composition containing thiabendazole copper and copper bromide, and its preparation method. For ease of explanation, the raw materials and composition range involved in the composition are described first, and then the process steps for preparing the composition are described. The preparation method involves copper bromide confinement stabilization treatment, thiabendazole copper microparticle treatment, dual copper source adjacent composite treatment, and post-treatment stabilization steps to obtain a synergistic bactericidal composition containing thiabendazole copper and copper bromide. The composition uses thiabendazole copper and copper bromide as bactericidal active ingredients, and forms a formulation system with stable dispersion and relatively slow release through the above preparation method.

[0021] Raw material description In this embodiment, thiabendazole copper can be commercially available thiabendazole copper technical that meets the requirements for pesticide formulation processing. The content of its active ingredient can be calculated based on the actual content of the technical. As the first fungicidal active ingredient in this composition, thiabendazole copper is mainly used to provide organic copper fungicidal activity.

[0022] Copper bromide: Copper bromide products can be produced using copper salt production lines, or commercially available industrial-grade, reagent-grade, or purified copper bromide products that meet the requirements for pharmaceutical processing. For enterprises with the capability to prepare copper salts or copper compounds, copper bromide can be obtained from copper oxide, copper hydroxide, basic copper salts, or other copper-containing raw materials through appropriate bromination reactions, filtration, concentration, and drying. If hydrated copper bromide is used, the amount of copper bromide mentioned in this specification is calculated based on the effective amount of CuBr2. Copper bromide serves as the second bactericidal active ingredient in this composition, used in conjunction with thiabendazole copper to form a dual-copper-source bactericidal system.

[0023] Porous carrier: One or more of the following materials that are permitted in pesticide formulations, such as attapulgite, diatomaceous earth, silica, montmorillonite, bentonite, and magnesium aluminum silicate, can be used. The porous carrier is used to adsorb or confine at least part of copper bromide, thereby reducing its tendency to be released free in the formulation system.

[0024] Protective colloid: One or more of the following can be used: polyvinylpyrrolidone, polyvinyl alcohol, gum arabic, sodium alginate, and sodium carboxymethyl cellulose. The protective colloid is used to improve the dispersion stability of copper bromide confined dispersion in the aqueous phase and reduce its disturbance to the thiabendazole copper microparticle dispersion system.

[0025] Weak complexing stabilizer: One or more of sodium citrate, sodium gluconate, sodium tartrate, and sodium acetate can be used. The weak complexing stabilizer is used to moderately adjust the state of copper ions to avoid the instantaneous release of copper ions too quickly during formulation preparation or the initial stage of drug application. It should be noted that the weak complexing stabilizer in this invention is not used to completely passivate copper ions, but to slow down their release rate so that they can still participate in the bactericidal effect.

[0026] Dispersant: One or more of lignin sulfonate, naphthalene sulfonate formaldehyde condensate, polycarboxylate dispersant, and alkyl aryl polyoxyethylene ether can be used; the dispersant is used to improve the dispersion uniformity of thiabendazole copper microparticles, porous carriers and copper bromide confined dispersions in aqueous systems, and to reduce particle agglomeration and sedimentation.

[0027] Wetting agent: Sodium dodecyl sulfate, sodium dodecylbenzene sulfonate, fatty alcohol polyoxyethylene ether, alkyl naphthalene sulfonate or one or more of these can be used; the wetting agent is used to improve the wetting speed of thiabendazole copper technical, porous carrier and filler in aqueous phase, so as to facilitate pre-dispersion and subsequent grinding.

[0028] Thickener: One or more of xanthan gum, magnesium aluminum silicate, sodium carboxymethyl cellulose, and polyvinyl alcohol can be used; the thickener is used to adjust the viscosity of the composition system, improve suspension stability, and reduce the settling rate during storage.

[0029] Antifreeze: One or more of ethylene glycol, propylene glycol, and glycerol can be used. Antifreeze is used to improve the stability of the composition under low temperature storage conditions and reduce low temperature crystallization, layering, or decreased fluidity.

[0030] Defoamer: Organosilicon defoamers can be used. Defoamers are used to reduce foam during shearing, grinding and mixing processes, and reduce the impact of foam on the stability of feeding, grinding and filling.

[0031] pH buffer: One or more of acetate buffer, citrate buffer, and phosphate buffer can be used. The pH buffer is used to adjust and stabilize the pH of the composition system so that it is within a range suitable for the dispersion of thiabendazole copper and the stable release of copper bromide.

[0032] The synergistic fungicidal composition of the present invention containing thiabendazole copper and copper bromide includes thiabendazole copper, copper bromide, porous carrier, protective colloid, weak complexing stabilizer, dispersant, wetting agent, and other auxiliary ingredients permitted for use in pesticide formulations.

[0033] The mass ratio of thiabendazole copper to copper bromide is 20:1 to 1:3; preferably 10:1 to 1:1; and even more preferably 5:1 to 3:1. Through screening of different ratios, it was found that when the amount of copper bromide is too low, its rapid supplementation effect on thiabendazole copper is not obvious; when the amount of copper bromide is too high, the proportion of releaseable copper ions in the system increases, which can easily lead to a decrease in formulation stability and an increase in leaf irritation. Therefore, controlling the mass ratio of thiabendazole copper to copper bromide within the above range is beneficial to taking into account the synergistic effect, stability and crop safety.

[0034] The composition may include the following components in parts by weight: 5-40 parts of thiabendazole copper; Copper bromide 0.5–15 parts; 0.5–12 parts of porous carrier; Protective colloid 0.1 to 5 parts; 0.05–2 parts of weak complexing stabilizer; 1-10 parts of dispersant; Wetting agent 0.5 to 5 parts; Thickener 0.05–3 parts; 0-8 parts antifreeze; Defoamer 0.05-1 part; pH buffer 0.05–2 parts; Add water or filler to bring the total to 100 parts.

[0035] The compositions of the present invention can be prepared as suspensions, wettable powders, or water-dispersible granules. Preferably, the composition is a suspension, which can better reflect the composite dispersion state of thiabendazole copper microparticles and copper bromide confined dispersions, making it easier to control the copper ion release rate and the dispersion stability of the formulation.

[0036] like Figure 1 As shown, the preparation method of the synergistic bactericidal composition containing thiabendazole copper and copper bromide of the present invention includes the following steps: S1. Preparation of copper bromide confined dispersion; S2. Prepare thiabendazole copper microparticle dispersion; S3. Copper bromide confined dispersion and thiabendazole copper microparticle dispersion are combined in close proximity to obtain a dual copper source composite dispersion system. S4. Add formulation auxiliary components to the dual copper source composite dispersion system to adjust the system stability and obtain a synergistic bactericidal composition containing thiabendazole copper and copper bromide.

[0037] This process treats copper bromide and thiabendazole copper separately before performing controlled compounding, rather than directly mixing the two active ingredients at once. This sequence reduces the direct impact of copper bromide on the thiabendazole copper dispersion system and improves the dispersion stability and release controllability of the resulting composition.

[0038] The following provides further explanation of each step in the preparation method: S1. Preparation of copper bromide confined dispersion Copper bromide is dissolved in water by stirring to obtain a copper bromide solution. A porous carrier, a protective colloid, and a weak complexing stabilizer are added to the copper bromide solution, and the mixture is stirred at 25–45°C for 30–90 minutes to allow at least part of the copper bromide to be adsorbed, confined, or stably dispersed by the protective colloid, thus obtaining a copper bromide confined dispersion.

[0039] The mass ratio of copper bromide to the porous carrier is 1:0.5 to 1:5, preferably 1:0.8 to 1:2.5; the mass ratio of copper bromide to the protective colloid is 1:0.05 to 1:0.8, preferably 1:0.1 to 1:0.4; and the mass ratio of copper bromide to the weak complexing stabilizer is 1:0.01 to 1:0.3, preferably 1:0.03 to 1:0.12.

[0040] When the amount of porous carrier is too low, the adsorption or confinement effect on copper bromide is insufficient, and the formulation is still prone to the problem of excessively rapid release of copper ions in the early stage; when the amount of porous carrier is too high, the viscosity of the system increases and may affect the suspension stability and spray dispersibility; therefore, selecting the above mass ratio range can better balance the confinement effect and the processability of the formulation.

[0041] The dosage ranges of the aforementioned protective colloid and weak complexing stabilizer are determined by considering the dispersion uniformity of the copper bromide confined dispersion, the system viscosity, the copper ion release rate, and the subsequent composite stability. When the dosage of the protective colloid is too low, its stabilizing effect on the copper bromide confined dispersion is insufficient, and the system is prone to local flocculation or sedimentation. When the dosage of the protective colloid is too high, the system viscosity increases, which may affect the subsequent grinding, compounding, and spray dispersibility. When the dosage of the weak complexing stabilizer is too low, its regulating effect on the copper ion release rate is insufficient. When the dosage of the weak complexing stabilizer is too high, the copper ion release may be excessively inhibited, thereby affecting the bactericidal activity of the composition.

[0042] The pH of the copper bromide confined dispersion is preferably controlled between 5.8 and 6.8. If the pH is too low, the system will be too acidic, which will easily affect the dispersion stability of the copper thiabendazole particles. If the pH is too high, the copper ions released by the copper bromide may precipitate unfavorably or make the release behavior unstable.

[0043] S2. Preparation of thiabendazole copper microparticle dispersion Thiamethoxam, dispersant, wetting agent, defoamer and some water are added to a dispersion vessel and sheared at 1000-3000 r / min for 10-40 minutes to obtain thiamethoxam pre-dispersion; then the thiamethoxam pre-dispersion is wet-milled to control the D90 of thiamethoxam particles to 2-5 μm to obtain thiamethoxam microparticle dispersion.

[0044] D90 refers to the particle size at which the cumulative volume percentage in the particle size distribution reaches 90%. When the D90 of thiabendazole copper particles is controlled within 2–5 μm, both dispersion stability and pathogen contact efficiency can be balanced. If the particle size is greater than 5 μm, the uniformity of thiabendazole copper distribution on the leaf surface and in the formulation system decreases. If the particle size is less than 2 μm, the grinding energy consumption increases significantly, the particle surface energy increases, and the risk of secondary aggregation may increase.

[0045] S3, adjacent composite Under stirring, the copper bromide confined dispersion obtained in step S1 is slowly added in batches or continuously to the thiabendazole copper microparticle dispersion obtained in step S2 over a period of 20–60 minutes. During the addition process, the system temperature is controlled at 20–35°C, the pH at 5.8–6.8, and the shearing speed at 800–2000 r / min. After the addition is completed, homogenization is continued for 20–50 minutes to obtain a dual copper source composite dispersion system.

[0046] In this embodiment, proximity compounding refers to the following: the copper bromide confined dispersion, treated with a porous carrier, protective colloid, and a weak complexing stabilizer, is added to the thiabendazole copper microparticle dispersion in batches or continuously and slowly. Under stirring, shearing, and pH control conditions, the copper bromide confined dispersion and the thiabendazole copper microparticles form a stable composite dispersion system. Through this compounding process, the copper bromide confined dispersion and the thiabendazole copper microparticles tend to be evenly distributed in the formulation system, which is beneficial for maintaining a more coordinated release and contact bactericidal process of the two copper sources after application.

[0047] Compared with the direct mixing method, the batch addition and controlled shearing in step S3 can avoid the sudden change in local ionic strength caused by the copper bromide solution entering the thiabendazole copper dispersion system all at once, thereby reducing flocculation, aggregation and sedimentation.

[0048] S4, Post-processing stabilization Thickener, antifreeze, defoamer, pH buffer and remaining water are added to the dual copper source composite dispersion system obtained in step S3, stirred evenly, filtered, and a synergistic bactericidal composition containing thiabendazole copper and copper bromide is obtained.

[0049] Preferably, the pH of the obtained composition is 6.0–7.0, the suspension rate is not less than 90%, and there is no obvious stratification, clumping, or crystallization after heat storage. This composition can be diluted with water for the prevention and control of bacterial diseases in crops, and is especially suitable for the prevention and control of bacterial angular leaf spot of cucumber, citrus canker, bacterial blight of rice, and bacterial wilt of tomato.

[0050] The preparation method of the present invention and the synergistic bactericidal composition obtained by the preparation method are further described below with reference to specific embodiments. Unless otherwise specified, the thiabendazole copper, copper bromide, porous carrier, protective colloid, weak complexing stabilizer, and other formulation adjuvants used in each embodiment can all be commercially available products that meet the requirements of pesticide formulation processing or purified products. The component dosages in each embodiment are based on 100 kg of composition; in actual production, the same mass ratio can be used for scaling up or down. The process parameters in each embodiment are used to illustrate specific implementation methods of the present invention and are not intended to limit the scope of protection of the present invention.

[0051] Example 1 This embodiment prepares a synergistic bactericidal composition suspension containing thiabendazole copper and copper bromide.

[0052] The dosage of each component is as follows, based on 100 kg of the composition: 25 kg of thiabendazole copper, 5 kg of copper bromide, 4 kg of attapulgite clay, 1.2 kg of polyvinylpyrrolidone, 0.35 kg of sodium citrate, 3 kg of sodium lignosulfonate, 1.5 kg of polycarboxylate dispersant, 1.5 kg of fatty alcohol polyoxyethylene ether, 0.4 kg of sodium dodecyl sulfate, 0.15 kg of xanthan gum, 0.5 kg of magnesium aluminum silicate, 5 kg of ethylene glycol, 0.3 kg of organosilicon defoamer, 0.5 kg of acetate buffer, and water to a final volume of 100 kg.

[0053] The preparation method is as follows: (1) Add copper bromide to 8 kg of water and stir at 500 r / min until the copper bromide is basically dissolved to obtain a copper bromide solution; add attapulgite, polyvinylpyrrolidone and sodium citrate to the copper bromide solution, stir at 1200 r / min for 60 minutes at 35℃, adjust the pH to 6.2, and obtain a copper bromide confined dispersion.

[0054] (2) Thiamethoxam, sodium lignosulfonate, polycarboxylate dispersant, fatty alcohol polyoxyethylene ether, sodium dodecyl sulfate, 0.15 kg of organosilicon defoamer and 30 kg of water were added to a dispersion vessel and sheared at 2000 r / min for 25 minutes to obtain thiamethoxam pre-dispersion; then the thiamethoxam pre-dispersion was sent to a sand mill for wet grinding for 70 minutes to control the thiamethoxam particle D90 to 3.4 μm to obtain thiamethoxam microparticle dispersion.

[0055] (3) Under stirring conditions of 1000 r / min, the copper bromide confined dispersion obtained in step (1) was added to the thiabendazole copper microparticle dispersion obtained in step (2) in three parts, with an interval of 10 minutes between each addition, and the total addition time was controlled to be 35 minutes; the system temperature was controlled to be 28℃ and the pH to be 6.3 during the addition process; after the addition was completed, homogenization was continued for 30 minutes to obtain the dual copper source composite dispersion system.

[0056] (4) The xanthan gum was pre-swelled with some water to obtain a xanthan gum solution; the xanthan gum solution, magnesium aluminum silicate, ethylene glycol, acetate buffer and the remaining organosilicon defoamer were added to the dual copper source composite dispersion system obtained in step (3), and stirred for 40 minutes. After filtration, a synergistic bactericidal composition suspension containing thiabendazole copper and copper bromide was obtained.

[0057] In this embodiment, the mass ratio of thiabendazole copper to copper bromide is 5:1.

[0058] Example 2 This embodiment is basically the same as Example 1, except that the amounts of each component are as follows: 24 kg of thiabendazole copper, 8 kg of copper bromide, 5 kg of silica, 1.2 kg of polyvinyl alcohol, 0.5 kg of sodium gluconate, 3.2 kg of sodium lignosulfonate, 1.8 kg of naphthalene sulfonate formaldehyde condensate, 1.2 kg of fatty alcohol polyoxyethylene ether, 0.4 kg of sodium dodecylbenzene sulfonate, 0.18 kg of xanthan gum, 0.6 kg of magnesium aluminum silicate, 4 kg of propylene glycol, 0.3 kg of organosilicon defoamer, 0.4 kg of citrate buffer, and water to a total of 100 kg.

[0059] During preparation, copper bromide, silica, polyvinyl alcohol, and sodium gluconate were stirred at 40°C for 70 minutes to obtain a copper bromide confined dispersion; the thiabendazole copper pre-dispersion was wet-milled to control the D90 to 3.1 μm; the copper bromide confined dispersion was added to the thiabendazole copper microparticle dispersion over 40 minutes, with the pH controlled at 6.1 and the shear speed at 1200 r / min during the addition process.

[0060] In this embodiment, the mass ratio of thiabendazole copper to copper bromide is 3:1.

[0061] Example 3 This embodiment is basically the same as Example 1, except that the amounts of each component are as follows: 20 kg of thiabendazole copper, 5 kg of copper bromide, 4 kg of diatomaceous earth, 1.0 kg of polyvinylpyrrolidone, 0.3 kg of sodium citrate, 3 kg of polycarboxylate dispersant, 2 kg of sodium lignosulfonate, 1.3 kg of fatty alcohol polyoxyethylene ether, 0.4 kg of sodium dodecyl sulfate, 0.16 kg of xanthan gum, 0.6 kg of magnesium aluminum silicate, 5 kg of ethylene glycol, 0.3 kg of organosilicon defoamer, 0.5 kg of acetate buffer, and water to a total of 100 kg.

[0062] During preparation, the pH of the copper bromide confined dispersion was controlled at 6.4, the D90 of the thiabendazole copper wet mill was 3.8 μm, the shear speed during adjacent compounding was 1000 r / min, and the compounding homogenization time was 40 minutes.

[0063] In this embodiment, the mass ratio of thiabendazole copper to copper bromide is 4:1.

[0064] Example 4 This embodiment is basically the same as Example 1, except that the amounts of each component are as follows: 15 kg of thiabendazole copper, 15 kg of copper bromide, 6 kg of diatomaceous earth, 1.2 kg of polyvinylpyrrolidone, 0.6 kg of sodium citrate, 3 kg of polycarboxylate dispersant, 2 kg of sodium lignosulfonate, 1.5 kg of fatty alcohol polyoxyethylene ether, 0.5 kg of sodium dodecyl sulfate, 0.2 kg of xanthan gum, 0.8 kg of magnesium aluminum silicate, 5 kg of ethylene glycol, 0.3 kg of organosilicon defoamer, 0.5 kg of acetate buffer, and water to a total of 100 kg.

[0065] During preparation, the copper bromide confined dispersion was stirred at 35°C for 80 minutes, and the D90 of the thiabendazole copper wet mill was 3.9 μm. The copper bromide confined dispersion was added over a period of 45 minutes, and the pH was controlled at 6.5 during the addition process.

[0066] In this embodiment, the mass ratio of thiabendazole copper to copper bromide is 1:1.

[0067] Example 5 This embodiment is basically the same as Example 1, except that the amounts of each component are as follows: Thiamethoxam 30kg, copper bromide 3kg, magnesium aluminum silicate 3kg, polyvinylpyrrolidone 1.5kg, sodium citrate 0.25kg, sodium lignosulfonate 3kg, polycarboxylate dispersant 1.5kg, fatty alcohol polyoxyethylene ether 1kg, sodium dodecyl sulfate 0.3kg, xanthan gum 0.12kg, ethylene glycol 4kg, silicone defoamer 0.25kg, acetate buffer 0.4kg, water to 100kg.

[0068] During preparation, the copper bromide confined dispersion was stirred at 30°C for 50 minutes, and the D90 of the thiabendazole copper wet mill was 2.9 μm. The addition time for adjacent compounding was 30 minutes, and the shearing speed was 1200 r / min.

[0069] In this embodiment, the mass ratio of thiabendazole copper to copper bromide is 10:1.

[0070] Example 6 This embodiment prepares a water-dispersible granule of a synergistic bactericidal composition containing thiabendazole copper and copper bromide.

[0071] The dosage of each component is as follows, based on 100 kg of the composition: Thiamethoxam 30kg, copper bromide 6kg, attapulgite 8kg, polyvinylpyrrolidone 2kg, sodium lignosulfonate 5kg, naphthalene sulfonate formaldehyde condensate 4kg, sodium dodecyl sulfate 2kg, ammonium sulfate 8kg, polyvinyl alcohol 1kg, kaolin to make up to 100kg.

[0072] The preparation method is as follows: (1) Dissolve copper bromide in 10 kg of water, add attapulgite and polyvinylpyrrolidone, stir at 35°C for 60 minutes to obtain copper bromide confined slurry.

[0073] (2) Mix thiabendazole copper, sodium lignosulfonate, naphthalene sulfonate formaldehyde condensate, sodium dodecyl sulfate, ammonium sulfate and kaolin evenly, and perform air jet milling to control the D90 of the milled material to be below 8μm to obtain thiabendazole copper premix powder.

[0074] (3) Add the copper bromide confined slurry obtained in step (1) to the thiabendazole copper premix powder obtained in step (2), knead for 30 minutes to obtain wet material.

[0075] (4) The wet material is extruded and granulated, dried at 45°C and sieved to obtain a water-dispersible granule of synergistic bactericidal composition containing thiabendazole copper and copper bromide.

[0076] This embodiment illustrates that the copper bromide confinement stabilization, thiabendazole copper microparticle or refinement, and adjacent compounding concepts of the present invention can also be applied to water-dispersible granules.

[0077] The following comparative examples are set up to compare with the above-described embodiments. Each comparative example examines the effects of single-agent thiabendazole copper, single-agent copper bromide, direct mixing method, no porous carrier, and no control of thiabendazole copper particle size on the performance of the composition. Except for the distinguishing features specifically mentioned, the types of raw materials, dosage standards, and preparation conditions of each comparative example are kept as consistent as possible with Example 1 in order to evaluate the effects of copper bromide confinement stabilization, thiabendazole copper micronization, and stepwise compounding process in this invention on the release performance, dispersion stability, fungicidal effect, and crop safety of the composition.

[0078] Comparative Example 1: Compared with Example 1, this comparative example does not include copper bromide, attapulgite, polyvinylpyrrolidone, and sodium citrate; the amount of thiabendazole copper used is 25 kg, and the remaining dispersants, wetting agents, thickeners, antifreeze agents, defoamers, and pH buffers are basically the same as in Example 1, with water added to a total of 100 kg; during preparation, thiabendazole copper and the adjuvants are directly pre-dispersed, ground, and mixed to obtain a single-agent suspension of thiabendazole copper.

[0079] Comparative Example 2: Compared with Example 1, this comparative example did not include thiabendazole copper; the amount of copper bromide was 5 kg, and the amounts of attapulgite, polyvinylpyrrolidone, sodium citrate and other additives were basically the same as in Example 1, with water added to a total of 100 kg; during preparation, copper bromide single-agent suspension was prepared according to the copper bromide confinement stabilization steps in Example 1.

[0080] Comparative Example 3: The formulation of this comparative example is exactly the same as that of Example 1, except that the preparation method is different. In this comparative example, copper bromide confined dispersion is not prepared in advance, nor is thiabendazole copper microparticle dispersion prepared separately. Instead, thiabendazole copper, copper bromide, attapulgite, polyvinylpyrrolidone, sodium citrate, dispersant, wetting agent, defoamer and water are added to the dispersion vessel at one time. After shearing for 30 minutes, wet grinding is performed for 70 minutes. Then thickener, antifreeze and buffer are added to obtain the direct mixing method compound composition.

[0081] This comparative example illustrates the difference in effectiveness between the direct mixing method and the stepwise confined proximity compounding method of the present invention under the same formulation conditions.

[0082] Comparative Example 4: Compared with Example 1, this comparative example does not include attapulgite. In preparation, copper bromide is mixed with polyvinylpyrrolidone, sodium citrate and water to obtain a copper bromide stabilized solution, which is then compounded with thiabendazole copper microparticle dispersion. Other steps are the same as in Example 1.

[0083] This comparative example illustrates the effect of porous carriers on copper bromide release control and formulation stability.

[0084] Comparative Example 5: Compared to Example 1, this comparative example involved shear dispersion only, without wet milling, during the preparation of the thiabendazole copper dispersion, resulting in thiabendazole copper particles with a D90 of approximately 10.8 μm. All other steps were the same as in Example 1.

[0085] This comparative example illustrates the effect of thiabendazole copper particle size control on dispersion stability and bactericidal effect.

[0086] The performance of the compositions obtained in the above examples and comparative examples is further illustrated below with reference to experimental examples. Each experimental example involves process parameters, formulation stability, copper ion release, combined toxicity, potted plant efficacy, batch stability, ratio range, and zeta potential. Unless otherwise specified, each experimental example uses samples obtained from the examples or comparative examples as the test objects, with each treatment set up in triplicate. The data in the table are the average values ​​of the results from each replicate. For tests involving concentration screening, the relevant indicators were calculated after measurements were performed according to the corresponding concentration gradient. The following experimental examples are only used to illustrate the implementation effects of the present invention and are not intended to limit the scope of protection of the present invention.

[0087] Experimental Example 1: To determine the effects of thiabendazole copper particle size, porous carrier dosage, and composite pH on the composition's performance, the basic formulation and preparation method of Example 1 were used as a basis, with only one process parameter changed while keeping the other raw material types, dosages, and operating conditions consistent. Specifically, the particle size group was used to investigate the effect of thiabendazole copper particle D90; the carrier group was used to investigate the effect of the mass ratio of copper bromide to porous carrier; and the pH group was used to investigate the effect of pH in adjacent composite stages.

[0088] In the experiment, the suspension rate was determined according to the conventional quality testing methods for pesticide suspension concentrates; the copper ion release rate was determined using the dialysis release method; and the antibacterial rate was determined using *Citrus canker* as the test bacteria at the same concentration of active ingredient. Each treatment was repeated three times, and the average value was taken. The results are shown in Table 1.

[0089] Table 1. Screening results of key process parameters: As shown in Table 1, when the D90 of thiabendazole copper particles is 3.4 μm and 4.8 μm, the suspension rates of the composition are 95.2% and 94.1%, respectively, and the antibacterial rates are 82.4% and 80.7%, respectively, indicating good overall performance. When the D90 is 1.6 μm, slight aggregation occurs in the system, and the suspension rate and antibacterial rate decrease. When the D90 increases to 7.6 μm, the suspension rate and antibacterial rate further decrease. Therefore, it is evident that both excessively small and excessively large particle sizes of thiabendazole copper are detrimental to the dispersion stability and antibacterial effect of the composition; controlling the D90 within the range of approximately 2–5 μm is more suitable.

[0090] Experimental Example 2: To evaluate the formulation stability of the compositions of the present invention, suspension rate, thermal storage stability and sedimentation were tested on the compositions obtained in Examples 1 to 5 and Comparative Examples 3 to 5.

[0091] The thermal storage stability test was conducted according to the conventional method for determining the thermal storage stability of pesticide suspension concentrates. The test conditions were storage at 54℃ for 14 days. The suspension rate was measured before and after thermal storage. The sedimentation after thermal storage was expressed as the volume fraction of the sedimentation layer after the sample had been left to stand for 24 hours. Each sample was tested three times, and the average value was taken. The results are shown in Table 2 and [Table data missing]. Figure 3 .

[0092] Table 2. Results of formulation stability tests: Figure 3 This is a comparison chart of the storage stability of the compositions. Figure 3 (a) shows the changes in suspension rate of Examples 1-5 and Comparative Examples 3-5 before and after heat storage. Figure 3 (b) shows the volume fraction of the settling layer after thermal storage for Examples 1-5 and Comparative Examples 3-5; as shown in Table 2 and Figure 3It can be seen that the initial suspension rate and the suspension rate after heat storage of the compositions obtained in Examples 1-5 are higher than those in Comparative Examples 3-5, and the volume fraction of the sedimentation layer is lower. Example 1 and Comparative Example 3 have the same formulation composition, but different preparation methods. After the direct mixing method was used in Comparative Example 3, the suspension rate decreased significantly after heat storage, and a small amount of crystallization occurred. After the copper bromide confinement stabilization and adjacent composite process were used in Example 1, the sedimentation and crystallization phenomena were significantly reduced. These results show that the technical effect of the present invention is related to the specific preparation method, and is not simply produced by the compounding of thiabendazole copper and copper bromide.

[0093] Experimental Example 3: To evaluate the effect of the preparation method of the present invention on the release behavior of copper bromide, the compositions obtained in Examples 1, 2, 3 and 4 were diluted with buffer water at pH 6.5 to the same total copper concentration, placed in dialysis bags, and shaken at 25°C. The external solution was collected at 0.5 hours, 2 hours, 6 hours and 24 hours, respectively, and the proportion of released copper ions to the total amount of releaseable copper in the sample was determined. It should be noted that each time point was repeated 3 times, and the results were averaged.

[0094] This test was used to simulate the copper ion release trend after the composition was diluted with water and applied to foliar water films. Each treatment was repeated three times, and the average value was taken. The results are shown in Table 3 and... Figure 2 .

[0095] Table 3. Copper ion release ratio: From Table 3 and Figure 2 It can be seen that Comparative Example 2, using copper bromide alone, exhibited a high release rate within 0.5 hours, indicating that copper bromide has a significant tendency for rapid release in the aqueous phase. Although Comparative Example 3 contained both thiabendazole copper and copper bromide, the release rate within 0.5 hours still reached 61.8% due to the use of a direct mixing method. Comparative Example 4 did not include a porous support, and although it underwent partial stabilization treatment, its release rate within 0.5 hours was still higher than that of Example 1. The initial release rate of Example 1 was lower than that of Comparative Examples 2-4, while the 24-hour release rate remained at 86.2%, indicating that the present invention did not completely inhibit copper ion release, but rather made the release process more gradual.

[0096] The results indicate that by using copper bromide confinement stabilization and adjacent composite processes, the burst release of copper bromide in the early stages of application can be reduced while maintaining its continuous release capacity, thereby reducing the risk of phytotoxicity caused by excessively high local copper ion concentrations.

[0097] Experimental Example 4: To evaluate the combined effect of thiabendazole copper and copper bromide, *Citrus canker* was used as the test pathogen. The inhibitory effects of Examples 1-5 and Comparative Examples 1-4 on the pathogen were determined by turbidimetric method. Five concentration gradients were set for each treatment, and each concentration was repeated three times. EC50 was calculated based on the inhibition rate, and the combined effect was evaluated by co-toxicity coefficient method.

[0098] The evaluation criteria for the co-toxicity coefficient (CTC) are as follows: CTC less than 80 indicates antagonistic effect; CTC between 80 and 120 indicates additive effect; CTC greater than 120 indicates synergistic effect; the results are shown in Table 4.

[0099] Table 4. Results of indoor combined virulence assays against *Citrus canker*: As shown in Table 4, thiabendazole copper and copper bromide exhibited a certain synergistic effect at different mass ratios, with the co-toxicity coefficient being higher in the range of 3:1 to 5:1. Comparative Example 3 and Example 1 had the same ratio of thiabendazole copper to copper bromide, but Comparative Example 3 used a direct mixing method, and its co-toxicity coefficient was lower than that of Example 1. This result indicates that thiabendazole copper and copper bromide have a basis for synergistic effect when combined, but the confined stabilization and adjacent composite preparation method of the present invention can further improve the stability of the synergistic effect.

[0100] It should be noted that the results in Table 4 do not indicate that other ratios are completely unusable, but rather that the range of 3:1 to 5:1 offers a good balance between synergistic effects, release control, and formulation stability, and is therefore considered a further preferred range.

[0101] Experimental Example 5: To evaluate the efficacy and safety of the combined formulations on plants, cucumber bacterial angular leaf spot was used as the test subject. A pot spraying method was employed. Cucumber seedlings with 3-4 true leaves were treated. Each pesticide was diluted with water at the same dosage of active ingredient and sprayed. 24 hours after spraying, cucumber bacterial angular leaf spot pathogens were inoculated. The disease index was assessed and the control effect calculated 7 days after inoculation. Simultaneously, leaf yellowing, scorching, and spotting were observed, and the phytotoxicity index was calculated on a scale of 0-10. Each treatment was replicated three times. Results are shown in Table 5. Figure 4 .

[0102] Table 5. Observation results of potted plant control efficacy and phytotoxicity against bacterial angular leaf spot of cucumber: Figure 4 This is a comparison chart of the efficacy and phytotoxicity of potted plants, where the bar chart represents the control effect and the line graph represents the phytotoxicity index; from Table 5 and Figure 4It can be seen that Examples 1-5 all have good control effects on bacterial angular leaf spot of cucumber, and the overall phytotoxicity index is lower than that of Comparative Examples 2 and 3. Comparative Example 3 is a compound composition prepared by direct mixing, which has a higher control effect than thiabendazole copper single agent, but the phytotoxicity index is also significantly higher. While improving the control effect, Examples 1 and 2 still have a low phytotoxicity index. This may be because the present invention can reduce the risk of leaf irritation caused by direct mixing by controlling the release state of copper bromide.

[0103] To further illustrate the leaf surface performance of each treatment, representative cucumber leaves from different treatment groups were selected as... Figure 7 , Figure 7 The images are only used to illustrate the typical leaf surface conditions of each treatment. The actual control effect and phytotoxicity index are based on the statistical results obtained from repeated experiments. As shown in Table 5, Comparative Example 2 mainly showed obvious local leaf edge scorching, Comparative Example 3 mainly showed yellowing of some leaves, and Comparative Example 4 showed a few visible spots. The leaves of Examples 1, 2, 3 and 5 were basically normal, and Example 4 only showed a few slight spots. The above results show that the present invention, through copper bromide confinement stabilization, thiabendazole copper micronization and adjacent compound treatment, can improve the control effect of bacterial angular leaf spot of cucumber while reducing the risk of leaf irritation that may be caused by direct mixing or copper bromide single treatment.

[0104] This experiment further demonstrates that the invention not only enhances indoor toxicity but also improves efficacy and safety in plants.

[0105] Experimental Example 6: To verify the effect of the preparation method of the present invention on batch repeatability, five batches of samples were prepared according to the methods of Example 1 and Comparative Example 3, respectively. The suspension rate and the inhibition rate against Citrus canker pathogens were tested for each batch of samples. The test concentration was the same, and each batch of samples was repeated three times. The average value of the results was taken. The results are shown in Table 6.

[0106] Table 6. Performance fluctuations of different batches of samples: As shown in Table 6, the suspension rate and antibacterial rate of different batches in Example 1 fluctuated less, while those of different batches in Comparative Example 3 fluctuated more. This result indicates that the direct mixing method is easily affected by the local dispersion state of copper bromide, the uniformity of feeding, and the grinding process. However, the present invention, by pre-preparing a copper bromide confined dispersion and then compounding it with a copper thiamethoxam microparticle dispersion in close proximity, can improve the distribution consistency of the two active ingredients in the system, thereby improving the batch stability of the product.

[0107] Experimental Example 7: To further verify the rationality of the mass ratio range of thiabendazole copper to copper bromide, the mass ratio of thiabendazole copper to copper bromide was adjusted based on the preparation method in Example 1. The co-toxicity coefficient, 0.5-hour copper ion release rate, and phytotoxicity index of the composition were measured. Except for the ratio of thiabendazole copper to copper bromide, the other adjuvant systems, copper bromide confinement treatment methods, thiabendazole copper particle size control conditions, and adjacent compounding conditions remained consistent. The results are shown in Table 7 and... Figure 5 .

[0108] Table 7. Comparison of the effects of different mass ratios of thiabendazole copper and copper bromide: From Table 7 and Figure 5 It can be seen that when the mass ratio of thiabendazole to copper bromide is 50:1 or 30:1, the amount of copper bromide is relatively low, and the co-toxicity coefficient of the composition does not reach a significant synergistic level, indicating that the synergistic supplementation effect of copper bromide on thiabendazole is insufficient. When the mass ratio is in the range of 20:1 to 1:3, the co-toxicity coefficient is greater than 120, indicating that the two have a synergistic effect. Among them, the co-toxicity coefficient is relatively high in the range of 5:1 to 3:1, and the copper ion release rate at 0.5 hours is at a relatively moderate level with a low phytotoxicity index, indicating that this ratio range can better balance the synergistic effect, release control, and crop safety. When the copper bromide ratio continues to increase to 1:5 and 1:10, the copper ion release rate increases significantly in the early stage, the phytotoxicity index increases, and the co-toxicity coefficient decreases instead, indicating that an excessively high copper bromide ratio is not conducive to obtaining a stable synergistic effect.

[0109] Therefore, the present invention determines the mass ratio of thiabendazole copper to copper bromide to be 20:1 to 1:3, preferably 10:1 to 1:1, and more preferably 5:1 to 3:1. This range is not determined solely based on formulation experience, but is determined comprehensively by combining the co-toxicity coefficient, copper ion release rate, and phytotoxicity index.

[0110] Experimental Example 8: To further evaluate the effect of different preparation methods on the electrical stability of the composition dispersion system, Zeta potential tests were performed on the samples obtained from Example 1, Comparative Example 3, Comparative Example 4, and Comparative Example 5. Before the test, each sample was diluted with deionized water to the same solid content, and the test was performed at 25°C. Each sample was tested three times, and the average value was taken. The results are shown in Table 8. Figure 6 .

[0111] Table 8. Zeta potential test results for different composition samples From Table 8 and Figure 6It can be seen that the absolute value of the Zeta potential in Example 1 is greater than that in Comparative Examples 3-5, indicating that the composition dispersion system has better electrical stability after copper bromide confinement stabilization, thiabendazole copper microparticleization and adjacent composite treatment. Comparative Example 3 uses a direct mixing method, Comparative Example 4 does not add a porous carrier, and Comparative Example 5 does not control the particle size of thiabendazole copper. Their absolute values ​​of Zeta potential are all low, indicating that their electrostatic repulsion stabilization effect between particles is relatively weak, and the system is more prone to sedimentation, flocculation or uneven dispersion. This result is consistent with the thermal storage stability results in Table 2, further demonstrating that the preparation method of the present invention helps to improve the dispersion stability of the composition.

[0112] Through the above technical solution, the present invention has at least the following beneficial effects: First, this invention stabilizes copper bromide through confinement treatment, ensuring that at least part of the copper bromide is adsorbed, confined, or stably dispersed under the action of a porous support or a protective colloid, thereby reducing its tendency for rapid release during formulation preparation and the initial stage of administration; as shown in Table 3 and... Figure 2 It can be seen that the copper ion release rate of Example 1 at 0.5h is lower than that of Comparative Examples 2-4, while it still maintains a high release rate at 24h. This indicates that the composition can reduce the initial burst release while maintaining the subsequent release capacity, which is beneficial to reducing the risk of leaf irritation caused by excessive local copper ion concentration.

[0113] Secondly, this invention micronizes thiabendazole copper and controls the D90 of the thiabendazole copper particles within the range of 2–5 μm, so that it has a better dispersion state in the composition. As shown in the particle size group results in Table 1, when the D90 of thiabendazole copper particles is 3.4 μm and 4.8 μm, the suspension rate and antibacterial rate of the composition are relatively high. Combining the comparison results of the particle size being too small and too large, controlling the D90 within the range of 2–5 μm is more suitable. When the particle size is too large, both the suspension rate and the antibacterial rate decrease. Therefore, this particle size control is beneficial to improving the dispersion uniformity of thiabendazole copper in the formulation system and the application interface.

[0114] Furthermore, this invention employs a stepwise compounding method, adding copper bromide confined dispersion to thiabendazole copper microparticle dispersion, and controlling the pH, temperature, shear rate, and homogenization time during the compounding stage to ensure that the two copper sources tend to form a stable compound state in the formulation system; as shown in Table 2 and... Figure 3 It can be seen that Examples 1-5 still exhibited high suspension rates and low sedimentation volume fractions after heat storage, indicating that the above preparation method can improve the storage stability of the composition; as shown in Table 8 and Figure 6 It can be seen that the absolute value of the Zeta potential in Example 1 is greater than that in Comparative Examples 3 to 5, which further illustrates that the preparation method helps to improve the electrical stability of the dispersion system.

[0115] Furthermore, this invention achieves a good balance between bactericidal synergy, release control, and crop safety by controlling the ratio of thiabendazole copper to copper bromide; as shown in Table 7 and... Figure 5 It can be seen that when the mass ratio of thiabendazole copper to copper bromide is in the range of 20:1 to 1:3, the co-toxicity coefficient is greater than 120, showing a synergistic effect; the co-toxicity coefficient is higher in the range of 5:1 to 3:1, and the copper ion release rate and phytotoxicity index at 0.5h are at a relatively reasonable level, indicating that this ratio range can take into account both bactericidal effect and safety.

[0116] In addition, from Table 5 and Figure 4 It can be seen that Examples 1-5 all have good potted plant control efficacy against bacterial angular leaf spot of cucumber, and the overall phytotoxicity index is lower than that of copper bromide single agent and direct mixing compound composition; this result shows that the composition of the present invention can reduce the crop phytotoxicity risk that may be caused by the rapid release of copper bromide while improving the control effect.

[0117] In summary, this invention improves the problems of excessively rapid release of copper ions, insufficient formulation dispersion stability, fluctuation in efficacy, and insufficient crop safety in the copper bromide-containing compound system by steps such as copper bromide confinement stabilization, thiabendazole copper microparticle formation, stepwise compounding with dual copper sources, and post-treatment stabilization. The resulting composition has good bactericidal and synergistic effects, release stability, storage stability, and crop safety.

[0118] The technical scope of this invention is not limited to the content described above. Those skilled in the art can make various modifications and variations to the above embodiments without departing from the technical concept of this invention, and all such modifications and variations should fall within the protection scope of this invention.

Claims

1. A method for preparing a synergistic bactericidal composition containing thiabendazole copper and copper bromide, characterized in that, Includes the following steps: S1: Copper bromide is dispersed in an aqueous phase with a porous carrier, a protective colloid, and a weak complexing stabilizer to obtain a copper bromide confined dispersion. S2: Pre-disperse thiabendazole copper with dispersant, wetting agent and water, and perform wet milling to control the D90 of thiabendazole copper particles to 2-5 μm to obtain thiabendazole copper microparticle dispersion. S3: Add the copper bromide confined dispersion obtained in step S1 in batches or continuously to the thiabendazole copper microparticle dispersion obtained in step S2, and perform adjacent compounding under shear conditions to obtain a dual copper source composite dispersion system. S4: Add formulation auxiliary components to the dual copper source composite dispersion system obtained in step S3 for post-treatment stabilization to obtain the synergistic bactericidal composition containing thiabendazole copper and copper bromide. The mass ratio of thiabendazole copper to copper bromide is 20:1 to 1:

3.

2. The method for preparing the synergistic bactericidal composition containing thiabendazole copper and copper bromide according to claim 1, characterized in that: The mass ratio of thiabendazole copper to copper bromide is 10:1 to 1:

1.

3. The method for preparing the synergistic bactericidal composition containing thiabendazole copper and copper bromide according to claim 1, characterized in that: In step S1, the mass ratio of copper bromide to porous carrier is 1:0.5 to 1:5; after adding copper bromide to water and stirring to dissolve it, porous carrier, protective colloid and weak complexing stabilizer are added, and the mixture is stirred at 25 to 45°C for 30 to 90 minutes to obtain the copper bromide confined dispersion.

4. The method for preparing the synergistic bactericidal composition containing thiabendazole copper and copper bromide according to claim 1, characterized in that: The porous carrier is selected from one or more of attapulgite, diatomaceous earth, silica, montmorillonite, bentonite, and magnesium aluminum silicate; the protective colloid is selected from one or more of polyvinylpyrrolidone, polyvinyl alcohol, gum arabic, sodium alginate, and sodium carboxymethyl cellulose; and the weak complexing stabilizer is selected from one or more of sodium citrate, sodium gluconate, sodium tartrate, and sodium acetate.

5. The method for preparing the synergistic bactericidal composition containing thiabendazole copper and copper bromide according to claim 1, characterized in that: In step S2, thiabendazole copper, dispersant, wetting agent, defoamer and water are added to a dispersion vessel and sheared at 1000-3000 r / min for 10-40 minutes to obtain thiabendazole copper pre-dispersion; then the thiabendazole copper pre-dispersion is wet-milled to obtain the thiabendazole copper microparticle dispersion.

6. The method for preparing the synergistic bactericidal composition containing thiabendazole copper and copper bromide according to claim 1, characterized in that: In step S3, the copper bromide confined dispersion is added to the thiabendazole copper microparticle dispersion over a period of 20 to 60 minutes. During the addition process, the system temperature is controlled at 20 to 35°C, the pH at 5.8 to 6.8, and the shearing speed at 800 to 2000 r / min. After the addition is completed, homogenization is continued for another 20 to 50 minutes.

7. The method for preparing the synergistic bactericidal composition containing thiabendazole copper and copper bromide according to claim 1, characterized in that: The dispersant is selected from one or more of lignin sulfonate, naphthalene sulfonate formaldehyde condensate, polycarboxylate dispersant, and alkyl aryl polyoxyethylene ether; the wetting agent is selected from one or more of sodium dodecyl sulfate, sodium dodecylbenzene sulfonate, fatty alcohol polyoxyethylene ether, and alkyl naphthalene sulfonate.

8. The method for preparing the synergistic bactericidal composition containing thiabendazole copper and copper bromide according to claim 1, characterized in that: In step S4, the formulation auxiliary components include a thickener, an antifreeze agent, an antifoaming agent, and a pH buffer; the thickener is selected from one or more of xanthan gum, magnesium aluminum silicate, sodium carboxymethyl cellulose, and polyvinyl alcohol; the antifreeze agent is selected from one or more of ethylene glycol, propylene glycol, and glycerol; and the pH buffer is selected from one or more of acetate buffer, citrate buffer, and phosphate buffer.

9. A synergistic bactericidal composition containing thiabendazole copper and copper bromide, characterized in that: The synergistic bactericidal composition containing thiabendazole copper and copper bromide is prepared by the preparation method described in claim 1.

10. The synergistic bactericidal composition containing thiabendazole copper and copper bromide according to claim 9, characterized in that: The synergistic bactericidal composition comprises, by weight: Thiamethoxam 5-40 parts, copper bromide 0.5-15 parts, porous carrier 0.5-12 parts, protective colloid 0.1-5 parts, weak complexing stabilizer 0.05-2 parts, dispersant 1-10 parts, wetting agent 0.5-5 parts, thickener 0.05-3 parts, antifreeze 0-8 parts, defoamer 0.05-1 part, pH buffer 0.05-2 parts, water to make up to 100 parts; The copper bromide, calculated as an effective amount of CuBr2, has a mass ratio of thiabendazole copper to copper bromide of 20:1 to 1:3; the synergistic bactericidal composition is in the form of a suspension.

Citation Information

Patent Citations

  • A thiodiazole copper water dispersible granule and its preparation method

    CN104255716B

  • Use of a bactericidal composition containing thiamethoxam zinc and thiamethoxam copper

    CN110810437B